Biopharmaceutical company Pharnext announced on Thursday that it had entered into discussions with financial analyst firm Edison Investment Research with a view to updating the valuation of its assets.

Last month, the neurodegenerative diseases specialist indicated that it considered itself to be sufficiently mature to value its assets and commercial potential.

In its press release, Pharnext explains that this valuation objective could eventually lead to a takeover of the company, with Pharnext currently favoring an agreement with a player in the pharmaceutical industry.

An independent financial analysis by Edison, a recognized research firm, should help determine the company's intrinsic value and target share price.

Edison, a financial analysis firm, knows the company well, and has been monitoring and analyzing its financial performance since 2020.

In its last publication, dated October 2022, Edison estimated Pharnext's total valuation at around 270 million euros, whereas its market capitalization today stands at 84 million euros.

Edison expects to publish a new financial analysis note by the end of Q1 2023.

Copyright (c) 2023 CercleFinance.com. All rights reserved.